JVR_2024v14n6

Journal of Vaccine Research 2024, Vol.14, No.6, 297-306 http://medscipublisher.com/index.php/jvr 303 large-scale experiments (Janssens et al., 2022). Meanwhile, the protective standards need to be redefined - although T-cell vaccines may not be able to completely block infections, they can significantly reduce the severe case rate and virus transmission (Clemens et al., 2018). 7.3 Successful application elements To achieve effective protection, three dimensions need to be focused on, Screen conserved T-cell epitopes with broad-spectrum cross-reactions and establish a CD4+/CD8+ epitope database for seasonal/pandemic strains (Savic et al., 2016); Optimize vaccine design to stimulate potent T-cell responses targeting stable viral regions (Isakova-Sivak et al., 2021); Apply cutting-edge technologies such as high-throughput sequencing to analyze the immune mechanism and overcome the influence of host immune heterogeneity on vaccine efficacy (Stacey et al., 2018). The final plan needs to balance the risk of immune escape and focus on maintaining long-term immune memory (Clemens et al., 2018; Zhou, 2024). 8 Current Challenges and Unresolved Issues 8.1 Limitations in antigen targeting and immune response Creating a universal flu vaccine faces obstacles due to limited understanding of T-cell recognition mechanisms. Although CD4+ and CD8+ T-cells show cross-strain defensive capabilities, the specific viral components (epitopes) triggering their activation remain undefined. For example, while memory CD4+ T-cells enhance antibody generation and amplify CD8+ activity, their exact binding targets require further identification (Grant et al., 2016; Valkenburg et al., 2018). Genetic variability complicates vaccine design. Differences in HLA profiles across populations lead to uneven T-cell activation, demanding deeper insights into how genetic diversity affects epitope recognition for equitable vaccine efficacy (Clemens et al., 2018; Isakova-Sivak et al., 2021). Overcoming this knowledge gap is critical for developing universally protective T-cell immunity. 8.2 Barriers to broad-spectrum vaccine design Achieving lasting, wide-ranging T-cell responses poses a major hurdle. Existing vaccines mainly trigger antibodies targeting specific strains, creating vulnerabilities against evolving variants. Improved strategies could focus on T-cell activation against stable viral elements (Sridhar, 2016; Schmidt and Lapuente, 2021). Translation challenges between preclinical and clinical stages present additional issues. Animal models demonstrate strong T-cell protection, but human immune variability often leads to divergent outcomes. Inconsistent measurement methods for T-cell activity further slow development (Clemens et al., 2018; Moraes et al., 2023; Liu et al., 2022). Closing these gaps requires enhanced tools for evaluating human immune responses. 8.3 Enhancing T-cell activation strategies Vaccine effectiveness relies on strategic adjuvant use and delivery optimization. Mucosal adjuvants such as IL-1β enhance tissue-resident memory T-cells (TRM), boosting frontline defenders in respiratory pathways (Lapuente et al., 2018; Jiang, 2024). This method increases both T-cell quantity and functional capacity. Coordinated CD4+ and CD8+ responses prove essential for viral clearance. Research confirms that combining Th1 cells with cytotoxic T-cells (CTLs) achieves effective pathogen elimination and durable defense (Valkenburg et al., 2018; Jansen et al., 2019). Vaccine formulations must therefore balance these cellular responses to ensure comprehensive, long-lasting protection against influenza diversity. 9 Future Outlook The development of a universal influenza vaccine for T-cell immunity requires close cooperation between laboratory research and clinical research. Some studies have shown that T cells (tissue-resident memory cells) play a key role in combating different influenza strains. However, there are still challenges in translating these findings from animal models to human applications. When antibody defense is unstable, comprehensive clinical data is of great significance for verifying the protective role

RkJQdWJsaXNoZXIy MjQ4ODYzNQ==